Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies
NCT01335256
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
BAY1000394
Sponsor
Bayer